Autoimmune & Cancer Small Molecules
Revolutionizing cancer therapy on a global basis by developing TCR therapies with the potential to treat a wide range of cancer types and patients.
Aduro’s three proprietary technology platforms (Live, Attenuated Double-Deleted Listeria (LADD), STING Pathway Activators, and B-select monoclonal antibodies) have the potential to transform the ...
Advaxis’ Lm Technology uses live, attenuated bioengineered Listeria monocytogenes (Lm) bacteria to stimulate the immune system to view tumor cells as potentially ...
Agenus uses the power of the immune system to develop innovative product candidates against cancer. The company has assembled a broad portfolio of antibodies including checkpoint inhibitors and ...
The company creates protein-based immunotherapies to treat cancer, autoimmune disorders, and other diseases.
Biologics. Amgen makes several therapeutic drugs that target serious disease. Many are derived from engineered monoclonal antibodies. Some target immune receptors.
Aminex Therapeutics, Inc., is a drug development company focused on discovery and development of a unique cancer drug therapy in the general category of cancer immunotherapies known as checkpoint ...
Antibody Drug Conjugates for cancer
Uses modified antibodies to generate immunotherapeutics.
Developing PRDM Gene and Protein Modulation Agents as Anti-Cancer Products
Artios develops cancer treatments that target DNA Damage Response (DDR) pathways in order to selectively kill cancer cells.
Atara Bio’s programs include T-cell product candidates and molecularly-targeted product candidates.
Atossa Genetics is a clinical-stage pharmaceutical company focused on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions.
Stem Cell Technologies, Fully Human Biologics Manufacturing Cell Lines, Regenerative Medicine, CAR-T Immunotherapy & Cancer Treatment.
A biopharmaceutical company dedicated to becoming a leader in the discovery and development of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer.
Develops next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), CAR T cell therapy, and TCR ...
Besins Healthcare produces anti-cancer drugs, and hormone therapies.
Bicycles are a new therapeutic modality combining the attributes of antibodies, small molecules and peptides within one molecule. Bicycles exhibit the affinity and selective ...
Novel molecular and cellular mechanisms that regulate tumor development and metastasis
Biolyse Pharma specializes in manufacturing and developing of sterile oncology drugs.
- Currently produces Paclitaxel for the treatment of cancer, known for its mild side effects when ...
Real-time cancer cell visualization for surgical applications. Blaze is working to develop Tumor Paint products and Optide*-based guided therapeutics.
The cancer immunotherapy research group is focused on the next generation of T cell engineering and creating a pipeline of T cell product candidates (CAR T cells) to treat a wide variety of liquid ...
A biopharmaceutical company. They discover, develop, and deliver medicines to treat serious disease.
Develops novel compounds for cancer treatment. The most advanced product candidate is ONT-380, an orally active and selective small molecule HER2 inhibitor.
Small Molecules, Biologics, Vaccines, The pipeline is comprised of antibody-based therapies and other protein-based therapeutics that modulate the immune system or directly target tumors. ...
Designing next generation immunotherapies based on gene-edited CAR T-cells
Personalized cancer treatment
Develops technology to activate the innate and adaptive arms of the immune system to recognize and ultimately destroy tumor cells.
CisThera’s mission is to develop innovative therapeutics to treat cancer, autoimmune diseases, as well as chronic kidney and liver diseases.
Anti-angiogenic compounds for cancer & AMD
Develops molecules to activate Toll like receptors. These can be used to stimulate the innate immune system.
Codiak plans to define and engineer exosomes with single or multiple payloads directed against specific intracellular targets.
Compliment Corporation is a start-up biotechnology company developing revolutionary therapeutics in oncology. Our mission is to improve cancer treatment by dramatically increasing the ...
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel agents that target the immune system to treat patients with cancer.
CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers
Develops anti-cancer drugs.
CytImmune’s nanotherapy platform, Aurimune, is a tumor-targeted Trojan horse. Aurimune selectively binds TNF receptors on blood vessel cells at the site of disease. Once bound, Aurimune unleashes ...
Develops cancer immunotherapies, drug conjugates (PDCs), T-cell engaging Probody bispecifics and ProCAR-NK cell therapies based on Protease-Activated Antibodies, 'Probodies'
Immunotherapy treatment for prostate cancer.
Focused on therapies for cancer and inflammatory diseases
Activating the immune system to eradicate cancer. Focuses on regulatory T cells.
Committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity.
Monoclonal antibodies targeting cancer
Research and development programs currently focus on potential treatments in HIV/AIDS, liver diseases, hematology and oncology, inflammatory and respiratory diseases, and cardiovascular conditions ...
Advancing first-in-class immunotherapy product candidates in oncology, as well as infectious and allergic diseases.
Our scientific innovation is based on a unique competency in medicinal chemistry, which is seamlessly integrated into a discovery process that is tailored to individual program needs. We have ...
Develops DNA vaccines and antigen-targeting immunotherapy to treat cancer and viral infections.
Isarna Therapeutics develops TGF-β inhibitors to effectively treat ophthalmic and fibrotic diseases and fight cancer. The company uses novel oligonucleotides and combination modalities to ...
The company leverages two technologies—CARs and TCRs—to activate a patient’s own T cells so that they attack cancer cells. Through genetic engineering, we insert a gene for a particular CAR or TCR ...
Multiple myeloma & other cancer treatments